MELAS: Phenotype Classification into Classic-versus-Atypical Presentations

References

1. 1.↵
   1. Finsterer J

   . Mitochondrial metabolic stroke: phenotype and genetics of stroke-like episodes. J Neurol Sci 2019;400:135–41 doi:10.1016/j.jns.2019.03.021 pmid:30946993

   CrossRefPubMed
2. 2.↵
   1. Lu JQ,
   2. Tarnopolsky MA

   . Mitochondrial neuropathy and neurogenic features in mitochondrial myopathy. Mitochondrion 2021;56:52–61 doi:10.1016/j.mito.2020.11.005 pmid:33220502

   CrossRefPubMed
3. 3.↵
   1. Chakrabarty S,
   2. Govindaraj P,
   3. Sankaran BP, et al

   . Contribution of nuclear and mitochondrial gene mutations in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome. J Neurol 2021;268:2192–207 doi:10.1007/s00415-020-10390-9 pmid:33484326

   CrossRefPubMed
4. 4.↵
   1. Wei X,
   2. Du M,
   3. Li D, et al

   . Mutations in FASTKD2 are associated with mitochondrial disease with multi-OXPHOS deficiency. Hum Mutat 2020;41:961–72 doi:10.1002/humu.23985 pmid:31944455

   CrossRefPubMed
5. 5.↵
   1. Yoo DH,
   2. Choi YC,
   3. Nam DE, et al

   . Identification of FASTKD2 compound heterozygous mutations as the underlying cause of autosomal recessive MELAS-like syndrome. Mitochondrion 2017;35:54–58 doi:10.1016/j.mito.2017.05.005 pmid:28499982

   CrossRefPubMed
6. 6.↵
   1. Yatsuga S,
   2. Povalko N,
   3. Nishioka J, et al

   ; Taro Matsuoka for MELAS Study Group in Japan. MELAS: a nationwide prospective cohort study of 96 patients in Japan. Biochim Biophys Acta 2012;1820:619–24 doi:10.1016/j.bbagen.2011.03.015 pmid:21443929

   CrossRefPubMed
7. 7.↵
   1. Hirano M,
   2. Ricci E,
   3. Koenigsberger MR, et al

   . Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord 1992;2:125–35 doi:10.1016/0960-8966(92)90045-8 pmid:1422200

   CrossRefPubMed
8. 8.↵
   1. Sproule DM,
   2. Kaufmann P

   . Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann N Y Acad Sci 2008;1142:133–58 doi:10.1196/annals.1444.011 pmid:18990125

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Alves CA,
   2. Teixeira SR,
   3. Martin-Saavedra JS, et al

   . Pediatric Leigh syndrome: neuroimaging features and genetic correlations. Ann Neurol 2020;88:218–32 doi:10.1002/ana.25789 pmid:32445240

   CrossRefPubMed
10. 10.↵
    1. Goto Y,
    2. Nonaka I,
    3. Horai S

    . A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990;348:651–53 doi:10.1038/348651a0 pmid:2102678

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Karicheva OZ,
    2. Kolesnikova OA,
    3. Schirtz T, et al

    . Correction of the consequences of mitochondrial 3243A>G mutation in the MT-TL1 gene causing the MELAS syndrome by tRNA import into mitochondria. Nucleic Acids Res 2011;39:8173–86 doi:10.1093/nar/gkr546 pmid:21724600

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Chin J,
    2. Marotta R,
    3. Chiotis M, et al

    . Detection rates and phenotypic spectrum of m. 3243A> G in the MT-TL1 gene: a molecular diagnostic laboratory perspective. Mitochondrion 2014;17:34–41 doi:10.1016/j.mito.2014.05.005 pmid:24846800

    CrossRefPubMed
13. 13.↵
    1. Pickett SJ,
    2. Grady JP,
    3. Ng YS, et al

    . Phenotypic heterogeneity in m.3243A>G mitochondrial disease: the role of nuclear factors. Ann Clin Transl Neurol 2018;5:333–45 doi:10.1002/acn3.532 pmid:29560378

    CrossRefPubMed
14. 14.↵
    1. Nesbitt V,
    2. Pitceathly RD,
    3. Turnbull DM, et al

    . The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation–implications for diagnosis and management. J Neurol Neurosurg Psychiatry 2013;84:936–38 doi:10.1136/jnnp-2012-303528 pmid:23355809

    Abstract/FREE Full Text
15. 15.↵
    1. Miyahara H,
    2. Matsumoto S,
    3. Mokuno K, et al

    . Autopsied case with MERRF/MELAS overlap syndrome accompanied by stroke-like episodes localized to the precentral gyrus. Neuropathology 2019;39:212–17 doi:10.1111/neup.12551 pmid:30972844

    CrossRefPubMed
16. 16.↵
    1. Malfatti E,
    2. Bugiani M,
    3. Invernizzi F, et al

    . Novel mutations of ND genes in complex I deficiency associated with mitochondrial encephalopathy. Brain 2007;130:1894–904 doi:10.1093/brain/awm114 pmid:17535832

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Mezuki S,
    2. Fukuda K,
    3. Matsushita T, et al

    . Isolated and repeated stroke-like episodes in a middle-aged man with a mitochondrial ND3 T10158C mutation: a case report. BMC Neurol 2017;17:217 doi:10.1186/s12883-017-1001-4 pmid:29237403

    CrossRefPubMed
18. 18.↵
    1. von Elm E,
    2. Altman DG,
    3. Egger M, et al; STROBE Initiative

    . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;20:1453–7 doi:10.1016/S0140-6736(07)61602-X pmid:18064739

    CrossRefPubMed
19. 19.↵
    1. Rahman S,
    2. Poulton J,
    3. Marchington D, et al

    . Decrease of 3243 A–>G mtDNA mutation from blood in MELAS syndrome: a longitudinal study. Am J Hum Genet 2001;68:238–40 doi:10.1086/316930 pmid:11085913

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Ng YS,
    2. Lax NZ,
    3. Blain AP, et al

    . Forecasting stroke-like episodes and outcomes in mitochondrial disease. Brain 2022;145:542–54 doi:10.1093/brain/awab353 pmid:34927673

    CrossRefPubMed
21. 21.↵
    1. Rahman S,
    2. Copeland WC

    . POLG-related disorders and their neurological manifestations. Nat Rev Neurol 2019;15:40–52 doi:10.1038/s41582-018-0101-0 pmid:30451971

    CrossRefPubMed
22. 22.↵
    1. Ishigaki H,
    2. Sato N,
    3. Kimura Y, et al

    . Linear cortical cystic lesions: characteristic MR findings in MELAS patients. Brain Dev 2021;43:931–38 doi:10.1016/j.braindev.2021.05.002 pmid:34049744

    CrossRefPubMed
23. 23.↵
    1. Di Stadio A,
    2. Pegoraro V,
    3. Giaretta L, et al

    . Hearing impairment in MELAS: new prospective in clinical use of microRNA, a systematic review. Orphanet J Rare Dis 2018;13:35 doi:10.1186/s13023-018-0770-1 pmid:29466997

    CrossRefPubMed
24. 24.↵
    1. El-Hattab AW,
    2. Adesina AM,
    3. Jones J, et al

    . MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab 2015;116:4–12 doi:10.1016/j.ymgme.2015.06.004 pmid:26095523

    CrossRefPubMed
25. 25.↵
    1. Chae HW,
    2. Na JH,
    3. Kim HS, et al

    . Mitochondrial diabetes and mitochondrial DNA mutation load in MELAS syndrome. Eur J Endocrinol 2020;183:505–12 doi:10.1530/EJE-20-0189 pmid:33107434

    CrossRefPubMed
26. 26.↵
    1. Cho JH,
    2. Kim JH,
    3. Choi JH, et al

    . Endocrine dysfunctions in patients with mitochondrial diseases. Int J Pediatr Endocrinol 2015;2015:O23 doi:10.1186/1687-9856-2015-S1-O23

    CrossRef
27. 27.↵
    1. Rahman J,
    2. Rahman S

    . Mitochondrial medicine in the omics era. Lancet 2018;391:2560–74 doi:10.1016/S0140-6736(18)30727-X pmid:29903433

    CrossRefPubMed
28. 28.↵
    1. Bhatia KD,
    2. Krishnan P,
    3. Kortman H, et al

    . Acute cortical lesions in MELAS syndrome: Anatomic distribution, symmetry, and evolution. AJNR Am J Neuroradiol 2020;41:167–73 doi:10.3174/ajnr.A6325 pmid:31806591

    Abstract/FREE Full Text
29. 29.↵
    1. Betts J,
    2. Jaros E,
    3. Perry RH, et al

    . Molecular neuropathology of MELAS: level of heteroplasmy in individual neurones and evidence of extensive vascular involvement. Neuropathol Appl Neurobiol 2006;32:359–73 doi:10.1111/j.1365-2990.2006.00731.x pmid:16866982

    CrossRefPubMedWeb of Science
30. 30.↵
    1. El-Hattab AW,
    2. Jahoor F

    . Assessment of nitric oxide production in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome with the use of a stable isotope tracer infusion technique. J Nutr 2017;147:1251–57 doi:10.3945/jn.117.248435 pmid:28515163

    Abstract/FREE Full Text
31. 31.↵
    1. Goldstein A,
    2. Rahman S

    . Seeking impact: global perspectives on outcome measure selection for translational and clinical research for primary mitochondrial disorders. J Inherit Metab Dis 2021;44:343–57 doi:10.1002/jimd.12320 pmid:33016339

    CrossRefPubMed